Search for a trial

1 results

A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab
and/or Ipilimumab in Subjects with Advanced Solid Tumors

Approved WMOCompleted

The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab in…

A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab and/or Ipilimumab in Subjects with Advanced Solid Tumors

A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab
and/or Ipilimumab in Subjects with Advanced Solid Tumors